How Much Does Vaginal Estradiol Cost in Wyoming?

Wyoming Retail Pricing: What You Will Actually Pay

The average cash price for vaginal estradiol across Wyoming retail pharmacies is approximately $120 per month in 2026. That figure covers the most commonly dispensed formulations: Estrace cream, the Vagifem/Yuvafem vaginal tablet, and the Estring vaginal ring. Branded manufacturer list prices hover around $280 per month, but very few patients pay that sticker price.

Pricing varies by formulation and pharmacy. Vaginal estradiol cream (0.01%) typically runs $90 to $150 for a 42.5 g tube at Wyoming independents and chain pharmacies. The vaginal tablet (10 mcg) costs $100 to $160 for a 30-count pack at most locations in Cheyenne, Casper, and Laramie. The Estring vaginal ring (2 mg, 90-day release) may cost $200 to $350 per ring without insurance, though the per-month cost drops to roughly $70 to $115 because each ring lasts three months.

Generic availability drives much of the price variation. The FDA approved generic estradiol vaginal cream and vaginal tablets, and these generics can cut costs 40% to 60% compared with branded equivalents [1]. Wyoming patients filling at large chains often find generics stocked automatically. Ask your pharmacist whether a generic substitution is available before filling a branded prescription.

A 2016 Cochrane systematic review of 30 trials (N=6,235) confirmed that low-dose vaginal estrogen preparations, including estradiol cream, tablets, and rings, were equally effective for treating vulvovaginal atrophy symptoms, with no significant difference in efficacy between formulations [2]. That means choosing the cheapest available option does not sacrifice clinical benefit.

Wyoming Medicaid Does Not Cover Vaginal Estradiol for GSM

Wyoming Medicaid does not include vaginal estradiol on its preferred drug list for genitourinary syndrome of menopause as of 2026. This affects roughly 60,000 Medicaid-enrolled women in the state. Patients covered by Wyoming Medicaid who need vaginal estrogen therapy face the full retail price unless they qualify for a manufacturer patient assistance program or use a 503A compounding pharmacy.

Prior authorization pathways exist for some hormonal therapies under Wyoming Medicaid, but vaginal estradiol for GSM specifically is excluded from coverage. This exclusion aligns with several other state Medicaid programs that classify vaginal estrogen as a "lifestyle" rather than medically necessary medication, despite the 2022 North American Menopause Society (NAMS) position statement recommending low-dose vaginal estrogen as first-line therapy for GSM symptoms [3].

Wyoming Medicaid patients do have one path worth exploring. If a provider documents recurrent urinary tract infections (UTIs) as the primary indication rather than vaginal atrophy alone, some state programs will reconsider coverage. A randomized trial published in the New England Journal of Medicine (N=233) found that vaginal estradiol reduced recurrent UTI episodes by 36% compared to placebo over 12 months [4]. That UTI-prevention indication can sometimes trigger a different prior authorization pathway.

Compounded Vaginal Estradiol in Wyoming: Legal and Accessible

Compounded vaginal estradiol is legal in Wyoming through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under state board of pharmacy oversight, as permitted by Section 503A of the Federal Food, Drug, and Cosmetic Act [5].

Wyoming has multiple 503A-licensed compounding pharmacies, concentrated in Cheyenne, Casper, Gillette, and Sheridan. Several of these pharmacies compound vaginal estradiol in cream or suppository form at prices ranging from $30 to $60 per month, substantially less than the $120 average cash price for FDA-approved products.

There are tradeoffs. Compounded medications do not undergo the same FDA review process for safety, efficacy, and manufacturing quality that commercially manufactured drugs do. The FDA has stated that compounded drugs "are not FDA-approved" and that "the quality and consistency of compounded drugs may vary" [5]. Compounded formulations may also use different bases and preservatives, which can affect local absorption and tolerability.

For patients choosing the compounded route, the Endocrine Society recommends confirming that the pharmacy holds current 503A licensure, uses United States Pharmacopeia (USP) standards for compounding, and provides certificates of analysis for raw estradiol powder [6]. Wyoming's Board of Pharmacy maintains an online registry of licensed compounding pharmacies.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Wyoming generally cover at least one vaginal estradiol formulation, though formulary placement varies. The three largest insurers operating in the state (Blue Cross Blue Shield of Wyoming, Cigna, and UnitedHealthcare) each include vaginal estradiol on their formularies, typically as a Tier 2 or Tier 3 preferred brand or generic.

Copays under commercial plans range from $10 to $45 per month for generic vaginal estradiol and $30 to $75 for branded formulations. Plans that use step therapy may require patients to try vaginal estradiol cream before covering the ring or tablet. The 2022 NAMS position statement notes that all low-dose vaginal estrogen products have equivalent efficacy, making step therapy clinically reasonable even if it limits patient choice of dosage form [3].

Medicare Part D covers vaginal estradiol, and most Part D plans in Wyoming list generic estradiol vaginal cream and tablets on Tier 1 or Tier 2. As of 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drug spending means that even patients taking multiple medications will not pay more than $2,000 total per year on covered prescriptions, including vaginal estradiol [7].

For patients with high-deductible health plans (HDHPs), vaginal estradiol qualifies as a preventive drug under IRS Notice 2019-45 if prescribed for certain preventive indications. Some HDHPs will cover it pre-deductible. This designation is not universal, so patients should check with their specific plan.

Manufacturer Savings Cards and Discount Programs

Manufacturer copay cards can reduce the out-of-pocket cost of branded vaginal estradiol to as little as $0 to $25 per fill for commercially insured patients. These cards typically cap total annual savings at $1,200 to $2,400.

Savings cards work in Wyoming the same way they work everywhere else in the U.S. The patient presents the card at the pharmacy alongside their insurance card. The manufacturer's card pays the difference between the patient's copay and the promotional price. Patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs are ineligible for manufacturer copay cards under the federal Anti-Kickback Statute [8].

Pharmacy discount programs offer another avenue. GoodRx, RxSaver, and similar platforms list vaginal estradiol cream as low as $45 to $75 per tube at Wyoming pharmacies. The Estring ring can be found for $180 to $250 through discount platforms. These discount prices apply regardless of insurance status and can be used when they beat the insured copay.

Patient assistance programs (PAPs) from manufacturers serve uninsured or underinsured patients with household incomes below 200% to 400% of the federal poverty level. Eligibility thresholds and benefit levels vary by manufacturer. Applications typically require income documentation and a signed prescription.

Telehealth Prescribing: Statewide Access in Wyoming

Telehealth prescribing of vaginal estradiol is fully legal in Wyoming. The state's 2021 telehealth parity law requires insurers to cover telehealth visits at the same rate as in-person visits. This expands access substantially in a state where the nearest gynecologist may be hours away from rural communities.

Wyoming's population density is the lowest in the nation at 5.8 persons per square mile. The state has only 97 OB-GYN physicians, creating significant access barriers for women in rural counties [9]. Telehealth platforms that specialize in hormone therapy can connect Wyoming patients with licensed prescribers who evaluate symptoms, order any needed labs, and prescribe vaginal estradiol. The prescription is then sent to the patient's preferred local or mail-order pharmacy.

A prescriber can diagnose GSM based on patient-reported symptoms and medical history without a physical exam in many cases. The American College of Obstetricians and Gynecologists (ACOG) states that clinical history alone is often sufficient to diagnose vulvovaginal atrophy, and that speculum examination is not always necessary before initiating low-dose vaginal estrogen [10].

Mail-order pharmacy fulfillment paired with telehealth can further reduce costs. Several national mail-order pharmacies offer generic vaginal estradiol cream for $40 to $60 per month with free shipping to Wyoming addresses, undercutting most local retail prices.

Clinical Dosing and Cost-per-Dose Breakdown

Understanding the standard dosing schedule helps patients predict their monthly spend more accurately. All vaginal estradiol formulations follow a similar pattern: a loading phase of daily application for two weeks, followed by twice-weekly maintenance [1].

For vaginal estradiol cream (0.01%), the standard maintenance dose is 1 g applied intravaginally twice weekly. A 42.5 g tube at $120 lasts approximately 5 weeks at maintenance dosing, bringing the effective monthly cost to about $95 to $100. During the initial two-week loading phase, patients use the tube faster, roughly doubling the first month's cost.

The 10 mcg vaginal tablet is inserted twice weekly at maintenance. A 30-count pack covers roughly 15 weeks of maintenance therapy, making the per-month cost approximately $27 to $43 depending on the purchase price. This makes the vaginal tablet the most cost-effective FDA-approved option for many Wyoming patients.

The Estring vaginal ring releases 7.5 mcg per 24 hours continuously for 90 days. A single ring replaces the need for twice-weekly dosing and costs $200 to $350 per ring, or $67 to $117 per month. Convenience is the primary advantage here.

A 2019 cost-effectiveness analysis published in Menopause found that vaginal estradiol tablets and rings were both more cost-effective over a 5-year horizon than vaginal cream when factoring in adherence rates and clinical outcomes [11]. Patients who struggle with cream applicators or twice-weekly scheduling may save money long-term by switching to the ring despite its higher unit cost.

Safety Profile and Long-Term Considerations

Low-dose vaginal estradiol produces minimal systemic absorption. Serum estradiol levels remain within the normal postmenopausal range (less than 20 pg/mL) with all three low-dose formulations [1]. The 2016 Cochrane review found no increased risk of endometrial hyperplasia, cardiovascular events, or venous thromboembolism with low-dose vaginal estrogen over the study periods examined [2].

The 2022 NAMS position statement concluded that low-dose vaginal estrogen does not require concomitant progestogen therapy for endometrial protection, even in women with an intact uterus [3]. This eliminates the cost of a second medication. The FDA black box warning on vaginal estradiol products reflects class labeling applied to all estrogen products rather than specific safety signals from low-dose vaginal formulations.

Dr. JoAnn Pinkerton, former executive director of NAMS, has stated: "Low-dose vaginal estrogen is one of the most effective and safest treatments we have for GSM. The systemic absorption is negligible, and the clinical benefit is significant" [3].

The ACOG Practice Bulletin No. 141 reinforces that "vaginal estrogen is the most effective treatment for vaginal atrophy" and that treatment can continue indefinitely as symptoms tend to recur upon discontinuation [10]. Wyoming patients should plan for ongoing costs when budgeting for therapy.

Practical Steps to Minimize Cost in Wyoming

The lowest-cost path for most Wyoming patients combines a generic vaginal estradiol tablet prescription, a discount card or manufacturer savings program, and mail-order fulfillment. That combination can bring monthly costs to $15 to $30. Patients with commercial insurance often pay even less after their plan's copay.

For uninsured patients, compounded vaginal estradiol from a licensed Wyoming 503A pharmacy at $30 to $60 per month represents the most affordable option. Patients should confirm 503A licensure and USP compliance before filling.

Wyoming Medicaid patients who cannot access coverage should apply to manufacturer PAPs and consider the compounded route simultaneously. Prescribers can also document recurrent UTI prevention as an indication, which may open a prior authorization pathway that GSM alone does not.

Every Wyoming patient should ask three questions at the pharmacy counter: Is a generic available? Does my plan cover this formulation? Is there a manufacturer card I can stack on top? Those three questions routinely cut the final price by 50% or more.